The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.
Pyrilutamide from Ligand Chem was used by several individuals to address hair loss, with mixed results and no significant side effects reported. Some users switched to Minoxidil Max for better value, while others noted no hair growth or only a reduction in shedding.
The user is seeking advice on maximizing hair growth while using oral finasteride, topical minoxidil, Nizoral, and microneedling, and is considering adding a laser diode cap, topical finasteride, retinol, and caffeine. Suggestions include using tretinoin with minoxidil for better absorption, switching to dutasteride, and considering RU58841 or pyrilutamide.
User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
A user experienced hair thinning due to traction alopecia from using Murray's Beeswax and is considering treatments like minoxidil and finasteride to reverse the damage. Another user suggests consulting a hair specialist, as the hair may not regrow if scar tissue has formed.
Using liposomal solutions with dutasteride, minoxidil, and tretinoin worsened hair loss due to buildup and scalp issues. Consulting a professional and returning to simpler treatments like finasteride and minoxidil improved the situation.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.
The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.
A user shared their successful hair loss regimen, which includes New Nordic Hair Gro vitamins, Shea Moisture Jamaican Black Castor Oil Leave-In Conditioner, and NAC supplements. They reported reduced hair shedding, thicker hair, and improved hair texture.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.
Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.
A potential treatment for hair loss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stem cell treatments; and ongoing clinical trials by doctors involved in the study.
Men with hair loss might have lichen planopilaris (LPP), which can mimic androgenetic alopecia, leading to misdiagnosis and ineffective treatment with finasteride or dutasteride. Proper diagnosis, including biopsies, is crucial to distinguish between androgenetic alopecia and conditions like LPP.
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.
Minoxidil, PRP, low-level light therapy, stem cell therapy, mesotherapy, Acell, and microneedling are discussed as treatments for thickening fine hairs in NW5 hair loss sufferers. A hair transplant may be necessary for significant improvement.
Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.